Bornocon, or Leuprolide Acetate Extended-Release Microspheres for Injection, does not have an ovulation-promoting effect. Leuprolide Acetate Extended-Release Microspheres for Injection is commonly used in the treatment of endometriosis, uterine fibroids, breast cancer and other diseases. Leuprolide Acetate Extended-Release Microspheres for Injection has an inhibitory effect on the pituitary-gonadal system, as well as an ovarian function inhibitory effect. Therefore, Leuprolide Acetate Extended-Release Microspheres for Injection is unable to promote ovulation, and its effect is to inhibit the normal ovulation function of the body, as well as to stop menstruation. Due to the inhibitory effect on estrogen concentration, Leuprolide Acetate Extended-Release Microspheres for Injection is commonly used clinically in the treatment of endometriosis, uterine fibroids, prostate cancer, and central precocious puberty, and it is also effective in estrogen receptor-positive breast cancer. The common adverse reactions of Leuprolide Acetate Extended-Release Microspheres for Injection are fever, cough, dyspnea and other symptoms of interstitial pneumonitis, as well as allergic symptoms, hepatic impairment, jaundice and other manifestations. The drug is contraindicated in patients who are allergic to the components of the drug, pregnant or breastfeeding women, and patients with suspected malignant diseases. It should be noted that Leuprolide Acetate Extended-Release Microspheres for Injection need to be used under the guidance of a doctor and avoid self-medication.